share_log

SVB Leerink Maintains Outperform on Calithera Biosciences, Raises Price Target to $18

Benzinga Real-time News ·  Aug 16, 2022 11:58

SVB Leerink analyst Jonathan Chang maintains Calithera Biosciences (NASDAQ:CALA) with a Outperform and raises the price target from $2 to $18.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment